Ironwood Pharmaceuticals Inc
IRWD3.200USD
-0.060-1.84%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
520.57MMarket Cap
18.09P/E TTM
More Details of Ironwood Pharmaceuticals Inc Company
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Ironwood Pharmaceuticals Inc Info
Ticker SymbolIRWD
Company nameIronwood Pharmaceuticals Inc
IPO dateFeb 03, 2010
CEOMccourt (Thomas A)
Number of employees253
Security typeOrdinary Share
Fiscal year-endFeb 03
Address100 Summer Street, Suite 2300
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02110
Phone16176217722
Websitehttps://www.ironwoodpharma.com/
Ticker SymbolIRWD
IPO dateFeb 03, 2010
CEOMccourt (Thomas A)
Company Executives of Ironwood Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas A. (Tom) Mccourt
Mr. Thomas A. (Tom) Mccourt
Chief Executive Officer, Director
Chief Executive Officer, Director
1.37M
+62.57%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
613.42K
+7.92%
Dr. Michael Shetzline, M.D., Ph.D.
Dr. Michael Shetzline, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
324.29K
-17.25%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
258.10K
+4.76%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Independent Chairman of the Board
Independent Chairman of the Board
208.84K
+27.47%
Mr. Jon R. Duane
Mr. Jon R. Duane
Independent Director
Independent Director
190.34K
+30.96%
Mr. John Minardo
Mr. John Minardo
Senior Vice President, Chief Legal Officer, Secretary
Senior Vice President, Chief Legal Officer, Secretary
167.65K
-4.42%
Ms. Marla L. Kessler
Ms. Marla L. Kessler
Independent Director
Independent Director
165.88K
+37.23%
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
117.94K
+61.69%
Ms. Tammi Gaskins
Ms. Tammi Gaskins
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas A. (Tom) Mccourt
Mr. Thomas A. (Tom) Mccourt
Chief Executive Officer, Director
Chief Executive Officer, Director
1.37M
+62.57%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
613.42K
+7.92%
Dr. Michael Shetzline, M.D., Ph.D.
Dr. Michael Shetzline, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
324.29K
-17.25%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
258.10K
+4.76%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Independent Chairman of the Board
Independent Chairman of the Board
208.84K
+27.47%
Mr. Jon R. Duane
Mr. Jon R. Duane
Independent Director
Independent Director
190.34K
+30.96%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
9.93%
Sarissa Capital Management, L.P.
9.79%
The Vanguard Group, Inc.
9.52%
BofA Global Research (US)
7.19%
BlackRock Institutional Trust Company, N.A.
6.84%
Other
56.73%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
9.93%
Sarissa Capital Management, L.P.
9.79%
The Vanguard Group, Inc.
9.52%
BofA Global Research (US)
7.19%
BlackRock Institutional Trust Company, N.A.
6.84%
Other
56.73%
Shareholder Types
Shareholders
Proportion
Hedge Fund
34.74%
Investment Advisor
26.03%
Investment Advisor/Hedge Fund
23.09%
Research Firm
9.06%
Individual Investor
2.91%
Family Office
0.41%
Pension Fund
0.26%
Sovereign Wealth Fund
0.13%
Bank and Trust
0.11%
Other
3.27%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
552
156.43M
96.30%
-36.74M
2025Q2
583
167.85M
103.73%
-32.54M
2025Q1
598
162.94M
100.73%
-39.13M
2024Q4
595
170.54M
106.57%
-31.05M
2024Q3
583
171.68M
107.49%
-32.57M
2024Q2
576
178.76M
112.46%
-25.68M
2024Q1
583
179.31M
112.83%
-3.43M
2023Q4
563
172.78M
110.50%
-13.64M
2023Q3
560
170.59M
109.32%
-22.08M
2023Q2
550
173.56M
111.70%
-13.28M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
16.15M
9.94%
+2.45M
+17.88%
Jun 30, 2025
Sarissa Capital Management, L.P.
15.92M
9.8%
-470.56K
-2.87%
Jun 30, 2025
The Vanguard Group, Inc.
15.62M
9.61%
+410.88K
+2.70%
Jun 30, 2025
BofA Global Research (US)
3.36M
2.07%
+1.93M
+135.06%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.10M
6.84%
+341.55K
+3.17%
Jun 30, 2025
Renaissance Technologies LLC
8.41M
5.18%
-1.53M
-15.44%
Jun 30, 2025
Acadian Asset Management LLC
6.55M
4.03%
+3.90M
+147.61%
Jun 30, 2025
Two Sigma Investments, LP
6.13M
3.78%
+3.02M
+97.14%
Jun 30, 2025
Kynam Capital Management LP
5.47M
3.37%
-356.11K
-6.12%
Jun 30, 2025
AQR Capital Management, LLC
6.17M
3.8%
+3.64M
+144.29%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Acquirers Small and Micro Deep Value ETF
1.29%
Amplify Etho Climate Leadership U.S. ETF
0.36%
Vanguard US Value Factor ETF
0.19%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.07%
Fidelity Enhanced Small Cap ETF
0.07%
WisdomTree US SmallCap Fund
0.06%
iShares Micro-Cap ETF
0.06%
Schwab Fundamental U.S. Small Company ETF
0.06%
Invesco RAFI US 1500 Small-Mid ETF
0.04%
View more
Acquirers Small and Micro Deep Value ETF
Proportion1.29%
Amplify Etho Climate Leadership U.S. ETF
Proportion0.36%
Vanguard US Value Factor ETF
Proportion0.19%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proportion0.14%
ProShares Ultra Nasdaq Biotechnology
Proportion0.07%
Fidelity Enhanced Small Cap ETF
Proportion0.07%
WisdomTree US SmallCap Fund
Proportion0.06%
iShares Micro-Cap ETF
Proportion0.06%
Schwab Fundamental U.S. Small Company ETF
Proportion0.06%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Ironwood Pharmaceuticals Inc?
The top five shareholders of Ironwood Pharmaceuticals Inc are:
Armistice Capital LLC holds 16.15M shares, accounting for 9.94% of the total shares.
Sarissa Capital Management, L.P. holds 15.92M shares, accounting for 9.80% of the total shares.
The Vanguard Group, Inc. holds 15.62M shares, accounting for 9.61% of the total shares.
BofA Global Research (US) holds 3.36M shares, accounting for 2.07% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.10M shares, accounting for 6.84% of the total shares.
Armistice Capital LLC holds 16.15M shares, accounting for 9.94% of the total shares.
Sarissa Capital Management, L.P. holds 15.92M shares, accounting for 9.80% of the total shares.
The Vanguard Group, Inc. holds 15.62M shares, accounting for 9.61% of the total shares.
BofA Global Research (US) holds 3.36M shares, accounting for 2.07% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.10M shares, accounting for 6.84% of the total shares.
What are the top three shareholder types of Ironwood Pharmaceuticals Inc?
The top three shareholder types of Ironwood Pharmaceuticals Inc are:
Armistice Capital LLC
Sarissa Capital Management, L.P.
The Vanguard Group, Inc.
Armistice Capital LLC
Sarissa Capital Management, L.P.
The Vanguard Group, Inc.
How many institutions hold shares of Ironwood Pharmaceuticals Inc (IRWD)?
As of 2025Q3, 552 institutions hold shares of Ironwood Pharmaceuticals Inc, with a combined market value of approximately 156.43M, accounting for 96.30% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.43%.
What is the biggest source of revenue for Ironwood Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Ironwood Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
